Verastem, Inc. (VSTM) filed an 8-K on November 4, 2025, reporting material updates, including third quarter 2025 financial results and strategic pipeline progress.
Financial Performance (Q3 2025): The commercial launch of AVMAPKI/FAKZYNJA CO-PACK for KRAS mt LGSOC generated \(11.2 million in net product revenue. Adoption is strong, supported by an NCCN Category 2A listing. The GAAP Net Loss widened significantly YoY to \)98.5 million (\(1.35/share) due to increased SG&A related to commercialization. Q3 GAAP Operating Expenses were \)52.0 million. The company maintains a solid balance sheet, e
...